Press Releases

Unites Real's AI-powered brokerage platform with REMAX's iconic real estate brand and global reach to deliver differentiated home buying and selling experience for over 180,000 real estate professionals and their clients across more than 120 countries and territories Combined company would have generated approximately $2.3 billion in annual revenue and $157 million in Adjusted EBITDA before synergies in 2025, on a pro forma basis Transaction is expected to be accretive to Real's earnings and EBITDA margin within first full year of closing Real to host conference call and webcast today at 8:30am ET The Real Brokerage Inc. (NASDAQ:REAX) ("Real"), a leading technology-powered real esta

Joby completes New York City's first-ever point-to-point electric vertical takeoff and landing (eVTOL) air taxi demonstration flights showcasing operational maturity and seamless integration into FAA-controlled airspace As a winning eIPP applicant, the Port Authority of New York and New Jersey worked with Joby to make these flights possible, advancing the path to commercial operations Joby's revolutionary aircraft has the potential to make skies over New York quieter and journeys faster Joby Aviation, Inc. (NYSE:JOBY), a company developing electric air taxis for commercial passenger service, today announced the completion of the first-ever point-to-point electric vertical takeoff

First-in-class SAPHNELO Pen now offers greater flexibility and convenience, reaching a wider group of patients AstraZeneca's SAPHNELO® (anifrolumab-fnia) has been approved in the US for self-administration as a once-weekly autoinjector, the SAPHNELO Pen, for the treatment of adult patients with systemic lupus erythematosus (SLE) on top of standard therapy. The approval by the US Food and Drug Administration (FDA) was based on results from the Phase III TULIP-SC trial, which showed that subcutaneous (SC) administration of SAPHNELO led to a statistically significant and clinically meaningful reduction in disease activity compared to placebo in participants with moderate to severe SLE whil

2026 Quarter Highlights Total revenue of $516.0 million, net income of $9.1 million, and Adjusted EBITDA of $155.0 million 2026 expected coal sales volumes over 95% committed and priced at the midpoint of 2026 guidance Record oil & gas royalty revenues and volumes, up 14.6% and 16.1%, respectively, year-over-year Completed $16.2 million in oil & gas mineral interest acquisitions during the 2026 Quarter Total and net leverage ratios as of March 31, 2026, were 0.73 times and 0.69 times, respectively Declares quarterly cash distribution of $0.60 per unit, or $2.40 per unit annualized Alliance Resource Partners, L.P. (NASDAQ:ARLP) ("ARLP" or the "Partnership") today reporte

Corsair Gaming, Inc. (NASDAQ:CRSR) ("Corsair" or the "Company"), a leading global provider and innovator of high-performance products for gamers, streamers, content-creators, gaming PC builders, and SIM Racing enthusiasts, today announced it has been named one of Newsweek's Most Trustworthy Companies in America 2026 reinforcing the Company's commitment to excellence, brand strength and innovation leadership. Recognition Based on Independent, Multi-Dimensional Analysis The Most Trustworthy Companies in America 2026 list, developed by Newsweek in partnership with Statista, evaluates companies using a comprehensive framework built on three core pillars: Customer Trust: Brand reliability

Key 1Q26 Highlights:  Strong consolidated net income leading to highest quarterly Adjusted EBITDA1 in company historySolid earnings per share (EPS) growth, which drove highest quarterly Adjusted EPS1 growth since 2021Strong cash flow from operating activities providing confidence in free cash flow1 guidance NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- Verizon Communications Inc. ((NYSE, NASDAQ:VZ) today reported first-quarter 2026 results that demonstrate accelerating momentum in its strategic transformation. The company delivered a strong quarter across core operating metrics, including its first positive first-quarter postpaid phone net adds since 2013. The achievements and performance

VDPHL01, a novel orally-administered extended-release minoxidil formulation, met all primary and all key secondary endpoints with high statistical significance in both active treatment arms evaluating once-daily (QD) and twice-daily (BID) administration of VDPHL01 Rapid and robust hair growth was achieved with VDPHL01 treatment as demonstrated by a mean increase in non-vellus target area hair count (TAHC) of 30.3 hairs/cm² (once daily dosing; p<0.0001) and 33.0 hairs/cm² (twice daily dosing; p<0.0001) versus 7.3 hairs/cm² for placebo at Month 6 Approximately 79.3% (QD) and 86.0% (BID) of patients reported any improvement in patient-reported outcomes (PRO) versus 35.6% of placebo patient

Dr. Mates grew Intra-Cellular from discovery and early innovation through commercialization of CAPLYTA® and a $14.6 billion acquisition by Johnson & Johnson Seaport Therapeutics ("Seaport" or the "Company"), a clinical-stage therapeutics company that is inventing and developing neuropsychiatric medicines, today announced the appointment of Dr. Sharon Mates to its Board of Directors. Dr. Mates served as the Co-Founder, Chairman, and Chief Executive Officer of Intra-Cellular Therapies, Inc. from inception of the company in June 2002 until its acquisition by Johnson & Johnson (J&J) in 2025 for approximately $14.6 billion. She has decades of experience in neuropsychiatry, guiding a company

Surf Air Mobility Inc. (NYSE:SRFM) ("Surf Air Mobility", or the "Company"), a leading air mobility platform, today announced the release of two new modules within SurfOSTM, the Company's proprietary AI-enabled operating system for private aviation and air mobility: a fuel optimization module and a crew reserve optimization module. Both modules are live within the Company's scheduled airline operations and bring mainline airline operational discipline to the scheduled commuter and regional air travel segment. Module 1: Fuel Optimization SurfOS now reconciles fuel uplift against vendor invoicing and provides flight-level visibility into fuel performance and cost across routes, aircraft, a

Core Scientific, Inc. (NASDAQ:CORZ) ("Core Scientific" or the "Company"), a leader in digital infrastructure for high-density colocation ("HDC"), today announced a multi-tiered strategy to scale its Pecos, Texas campus to approximately 1.5 gigawatts ("GW") of gross power, or approximately 1.0 GW of leasable power. Earlier this year, Core Scientific began transforming its Pecos campus, where 300 megawatts ("MW") of gross power capacity are currently used for bitcoin mining, into a data center campus for AI infrastructure. The first data hall has reached a critical construction milestone, with its interior foundational footings set, marking the start of the next phase of construction. Preca

REDWOOD CITY, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER) ("Seer" or the "Company"), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that its Board of Directors (the "Board") has thoroughly reviewed and unanimously rejected the revised unsolicited, non-binding proposal received on April 24, 2026 from Bradley L. Radoff and Michael Torok, together with certain of their affiliates (the "Radoff-JEC Group"), to acquire all of the outstanding shares of Seer's Class A common stock for $2.35 per share in cash plus a contingent value right (the "Revised Proposal"). "The Radoff-JEC Group's proposal significantly undervalues Seer in li

GOLETA, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Aeluma, Inc. (NASDAQ:ALMU), a semiconductor company specializing in high-performance, scalable technologies for mobile, AI, defense and aerospace, robotics, automotive, AR/VR, and quantum, announced today it has appointed Willy Rachmady, Ph.D. as its Vice President of Strategic Partnerships and Ecosystem. In this role, Dr. Rachmady will lead foundry and ecosystem partnerships, customer engineering, and the company's technology commercialization strategy spanning silicon photonics and compound semiconductor platforms. Dr. Rachmady brings more than 20 years of technical and strategic leadership in advanced semiconductor technologies to Aelu

NASHVILLE, Tenn., April 27, 2026 (GLOBE NEWSWIRE) -- Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it will report its financial results for the first quarter ended March 31, 2026, on Monday, May 11, 2026, after the market close. The Company will also post its first quarter Letter to Stockholders to the "Investors" section of its website, harrow.com. Harrow will host a conference call and live webcast at 8:00 a.m. Eastern Time on Tuesday, May 12, 2026, to discuss the results and provide a business update. Conference Call InformationParticipants can access the live webcast of Harrow's presentation on the "Investors

Data, generated in the lab of Dr. Amir Horowitz of the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai, demonstrated that all tested patient-derived tumor samples (n=7) responded to IM1240 treatment New data shows that the NKG2A arm significantly enhanced anti-tumor activity in all samples and improved the therapeutic index Immune cell structures known as a hallmark of effective anti-tumor immune response and favorable prognosis, were induced by IM1240 in a patient-derived non-small cell lung cancer (NSCLC) biopsy, corresponding with IM1240 anti-tumor efficacy   REHOVOT, Israel, April 27, 2026 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Compa

ORKA-001 achieved 63.5% (40/63) PASI 100 at Week 16 Favorable safety profile consistent with the IL-23p19 class Updated Phase 1 PK/PD data continue to support the potential for once-yearly dosing, with longer-term EVERLAST-A data expected in 2H 2026 Management to host a conference call today at 8:00 a.m. ET MENLO PARK, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases, today announced positive interim results from its EVERLAST-A Phase 2a trial of ORKA-001, a novel half-life extended IL-23p19 monoclonal ant

WARSAW, Ind., April 27, 2026 (GLOBE NEWSWIRE) -- Lakeland Financial Corporation (Nasdaq Global Select/LKFN), parent company of Lake City Bank, today reported record first quarter net income of $26.5 million for the three months ended March 31, 2026, which represents an increase of $6.4 million, or 32%, compared to net income of $20.1 million for the three months ended March 31, 2025. Diluted earnings per share of $1.04 for the first quarter of 2026 also represents a record first quarter performance and increased $0.26, or 33%, compared to $0.78 for the first quarter of 2025. On a linked quarter basis, net income decreased $3.4 million, or 11%, from $29.9 million. Diluted earnings per share

GE HealthCare (NASDAQ:GEHC) is announcing that members of its management team will present at the following upcoming investor conferences. Bank of America's 2026 Health Care Conference – Tuesday, May 12, 2026 at 10:40 am PT / 1:40 pm ET / 12:40 pm CT Jefferies Global Healthcare Conference – Wednesday June 3, 2026 at 9:20 am ET / 8:20 am CT Webcasts for each event can be accessed on the GE HealthCare website: https://investor.gehealthcare.com/news-events/events on the dates and times listed above. About GE HealthCare Technologies Inc. GE HealthCare is a leading global healthcare solutions provider of advanced medical technology, pharmaceutical diagnostics, and AI, cloud and soft

Guangzhou, China, April 27, 2026 (GLOBE NEWSWIRE) -- Youxin Technology Ltd (NASDAQ:YAAS) (the "Company" or "Youxin Technology"), a software as a service ("SaaS") and platform as a service ("PaaS") provider committed to helping retail enterprises digitally transform their businesses, today announced that on April 21, 2026, the Company entered into a definitive share acquisition agreement (the "Agreement") with seven shareholders of YATOP Group Limited (the "YATOP Shareholders") to acquire 18% of the equity interests in YATOP Group Limited ("YATOP"), a leading cross-border advertising and branding service growth partner. Pursuant to the Agreement, the Company agrees to acquire 18% of the eq

Phase 3 HAELO trial of lonvoguran ziclumeran (lonvo-z) met primary and all key secondary endpoints; favorable safety and tolerability data observed Single dose of lonvo-z freed most patients from both attacks and ongoing therapy for six-month efficacy evaluation period, demonstrating its potential to be the first and only one-time HAE treatmentRolling biologics license application (BLA) submission initiated with the U.S. Food and Drug Administration (FDA); anticipate U.S. launch in the first half of 2027, if approvedIntellia to host webcast today at 8:00 a.m. ET CAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading biopharmaceutical comp

Valmont® Industries, Inc. (NYSE:VMI), a global leader that provides products and solutions to support vital infrastructure and advance agricultural productivity, today announced that management will participate in Gabelli's 17th Annual Value Investor Conference in Omaha, NE. Avner M. Applbaum, President and Chief Executive Officer and Renee Campbell, Senior Vice President, Capital Markets and Risk, will participate in a fireside chat at 10:30 AM CT on Friday, May 1, 2026. Investors interested in accessing the Company's presentation may register to access the live event here. All registrants will receive a link to the event upon registration. About Valmont Industries, Inc. For more than